News

Endo president and chief executive officer Rajiv De Silva said: "Endo’s proposal would provide Auxilium shareholders a substantial premium and immediate cash value for their investment in Auxilium,

Under the terms of agreement, Pfizer will gain an exclusive, worldwide option to license and use MedGenesis’ glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery

In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Merck’s once-daily DPP-4 inhibitor JANUVIA® (sitagliptin) 50 mg, which is the standard starting dose for

Significant pre-launch activities are well underway as PTC prepares for the commercial launch of Translarna™ (ataluren) in the European Union. In August of this year, Translarna received approval

According to IMS, for the 12 months ending July 2014, the US market for Ketorolac approximated $34 million. As with all products in Sagent’s portfolio, Ketorolac features Sagent’s

A statistically significant and clinically relevant response was seen in a prospectively-identified, substantial sub-group of patients with moderate to severe pain who had relatively intact sensory responses as

The proceeds will be used to finance the Company’s registration program for the natriuretic peptide Ularitide in acute heart failure. "This is a pivotal time for our Company.

Odanacatib, which is firm’s investigational once-weekly cathepsin K inhibitor, has reached the primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with

According to Hungarian news agency MTI, the company’s research and development division has produced a drug comprising deuterium-depleted water or DDW, which has potential to trim down the